Last Updated: November 20, 2026

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE Drug Patent Profile

« Back to Dashboard


When do Ibuprofen And Phenylephrine Hydrochloride patents expire, and when can generic versions of Ibuprofen And Phenylephrine Hydrochloride launch?

Ibuprofen And Phenylephrine Hydrochloride is a drug marketed by Perrigo R And D and is included in one NDA.

The generic ingredient in IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE is ibuprofen; phenylephrine hydrochloride. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the ibuprofen; phenylephrine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ibuprofen And Phenylephrine Hydrochloride

A generic version of IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE was approved as ibuprofen; phenylephrine hydrochloride by PERRIGO R AND D on July 3rd, 2014.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE?
  • What are the global sales for IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE?
  • What is Average Wholesale Price for IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE?
Summary for IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE
Recent Clinical Trials for IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of North Carolina, Chapel HillPHASE4
Ache Laboratorios Farmaceuticos S.A.Phase 3
PfizerPhase 3

See all IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE clinical trials

Pharmacology for IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

US Patents and Regulatory Information for IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo R And D IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE ibuprofen; phenylephrine hydrochloride TABLET;ORAL 203200-001 Jul 3, 2014 OTC No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Ibuprofen and Phenylephrine Hydrochloride Market Dynamics, FDA Risk, and Financial Trajectory

Last updated: November 18, 2026

The ibuprofen and phenylephrine hydrochloride combination is an over-the-counter oral product used for temporary relief of nasal congestion, sinus pressure, headache, fever, and minor aches. Its commercial position is weakening because FDA review concluded that oral phenylephrine is ineffective as a nasal decongestant at the labeled dose. The combination has limited patent protection, substantial generic competition, and a regulatory-driven reformulation risk. Financial exposure is concentrated in branded and private-label cold-and-sinus products rather than in a separately reported pharmaceutical franchise.

What is the ibuprofen and phenylephrine hydrochloride combination?

The product combines:

Ingredient Typical OTC role Typical adult dose in combination products
Ibuprofen Analgesic, antipyretic, anti-inflammatory 200 mg
Phenylephrine hydrochloride Oral nasal decongestant 10 mg

The combination is sold under brand, store-brand, and generic labels. Haleon’s Advil Sinus Congestion & Pain is a prominent branded example in the U.S. market. Products can differ by strength, tablet count, labeling, packaging, and whether they are marketed as tablets, caplets, or liquid-filled capsules.

Ibuprofen remains a widely used OTC analgesic. Phenylephrine is the commercial vulnerability because the FDA has determined that the available data do not support its effectiveness as an oral nasal decongestant at the current monograph dose.

What is the FDA status of oral phenylephrine?

FDA’s current position is that oral phenylephrine is not effective as a nasal decongestant at the labeled OTC dose. In September 2023, an FDA advisory committee voted unanimously that available data did not support the efficacy of oral phenylephrine. FDA issued a proposed order in November 2024 to remove oral phenylephrine from the OTC monograph for nasal decongestants. The proposal does not immediately ban products or require an immediate market withdrawal. Products may continue to be sold while the rulemaking process proceeds.

The regulatory distinction is important:

Issue Current position
Ibuprofen Remains an accepted OTC analgesic active ingredient
Oral phenylephrine Subject to FDA proposed removal from the OTC nasal-decongestant monograph
Existing combination products May remain marketed during the regulatory process, subject to applicable labeling and manufacturing requirements
Long-term labeling At risk of losing the oral nasal-decongestant indication
Combination economics Dependent on whether manufacturers reformulate, relabel, or discontinue products

The FDA action affects the decongestant claim, not ibuprofen’s analgesic or antipyretic status. A manufacturer could potentially preserve an ibuprofen product, but it could not continue to market the same oral phenylephrine claim if FDA finalizes the proposed order and establishes an effective compliance date. (FDA, 2023; FDA, 2024)

When could ibuprofen and phenylephrine products lose exclusivity?

The combination has no meaningful modern exclusivity period comparable to a new prescription drug. It is generally sold through the OTC monograph system, where approved active ingredients, doses, indications, labeling, and conditions of use are established by regulation.

There are three distinct forms of exclusivity:

Exclusivity category Position for ibuprofen/phenylephrine
New-drug exclusivity Generally not applicable to monograph-compliant products
Orange Book patent exclusivity Usually not the principal barrier for these OTC combinations
Brand and trade-dress protection Can remain commercially relevant but does not block generic entry
Retail distribution advantage Often more important than legal exclusivity

Generic entry has already occurred. Store brands and private-label products compete on price and retailer placement. The principal commercial protection for branded products is consumer recognition, shelf placement, advertising, packaging, and retailer relationships.

What patents protect ibuprofen and phenylephrine hydrochloride products?

The active ingredients are old and broadly available. Ibuprofen was discovered and commercialized decades ago, while phenylephrine hydrochloride has also been used in OTC products for many years. Core composition-of-matter patent protection is not commercially relevant.

Potential patent categories include:

  • Tablet or caplet formulation patents
  • Liquid-filled capsule technology
  • Modified-release or timed-release formulations
  • Manufacturing processes
  • Packaging and delivery systems
  • Particular dosage combinations
  • Method-of-use claims

For standard immediate-release 200 mg ibuprofen/10 mg phenylephrine products, the practical barrier is low. Any surviving formulation patent would need to cover a commercially important product feature and withstand invalidity and noninfringement challenges. Older formulation patents may exist, but they do not create a broad market barrier to ordinary immediate-release generic products.

What is the Orange Book status of the combination?

The FDA Orange Book is principally designed for approved prescription and certain approved nonprescription drug applications. Many OTC monograph products do not have an NDA-based Orange Book listing comparable to prescription products.

For this combination, the relevant competitive framework is usually:

  1. OTC monograph compliance;
  2. FDA labeling and ingredient status;
  3. Trademark and trade-dress rights;
  4. Formulation-specific patents, if any;
  5. Manufacturing and retail execution.

An Orange Book patent listing should not be assumed merely because a branded OTC product has a recognizable name. Product-specific NDA and patent status can differ by manufacturer and dosage form. (FDA, 2025a)

How strong is the patent estate for ibuprofen and phenylephrine?

The patent estate is weak as a market-wide barrier and moderate only where a manufacturer owns a narrow, commercially differentiated formulation.

Patent factor Assessment
Active-ingredient patents Expired or commercially irrelevant
Basic combination claims Vulnerable to prior-art and obviousness challenges
Standard immediate-release tablets Low protection
Specialized delivery systems Potentially stronger, but product-specific
Manufacturing know-how Can reduce substitution speed without creating legal exclusivity
Trade dress and trademarks Useful against copying of branding, not against generic products

The likely commercial risk is regulatory displacement rather than patent litigation. FDA’s proposed action against oral phenylephrine could eliminate the product’s principal congestion indication even if no competitor asserts a patent.

How does the combination compare with competing cold-and-sinus drugs?

The product competes across two distinct dimensions: pain relief and decongestion.

Product type Analgesic Decongestant Key commercial issue
Ibuprofen/phenylephrine Ibuprofen Oral phenylephrine FDA efficacy and future labeling risk
Acetaminophen/phenylephrine Acetaminophen Oral phenylephrine Same phenylephrine exposure
Ibuprofen/pseudoephedrine Ibuprofen Pseudoephedrine Stronger decongestant positioning but retail restrictions
Acetaminophen/pseudoephedrine Acetaminophen Pseudoephedrine Established alternative with purchase controls
Ibuprofen alone Ibuprofen None Lower regulatory risk but narrower indication
Acetaminophen alone Acetaminophen None Large, established pain-relief category

Pseudoephedrine products may benefit from the weakness of oral phenylephrine, but they face purchase restrictions under the Combat Methamphetamine Epidemic Act and state-level controls. Those restrictions affect convenience, inventory handling, and retailer participation. A manufacturer replacing phenylephrine with pseudoephedrine may improve efficacy positioning but increase operational and compliance costs.

What market dynamics are affecting sales?

The combination is exposed to four market forces.

FDA-driven product substitution

Retailers and manufacturers may reduce purchases of products containing oral phenylephrine before FDA completes its rulemaking. The risk is greatest for products whose value proposition depends on congestion relief rather than pain relief.

Private-label pricing

Store brands and generic manufacturers can sell comparable products at lower prices. The active ingredients are inexpensive, and the product does not require a complex biological manufacturing platform. Retailer bargaining power can compress branded gross margins.

Seasonal demand

Sales are concentrated in the fall and winter respiratory season. Demand is affected by influenza, respiratory syncytial virus, common-cold activity, consumer travel, and weather. This creates inventory and forecasting risk, especially if FDA developments occur before the peak season.

Consumer migration

Consumers seeking congestion relief may move toward pseudoephedrine products, topical nasal decongestants, saline products, or nonpharmacologic treatments. Consumers seeking pain relief may shift to standalone ibuprofen or acetaminophen.

What is the financial trajectory for manufacturers?

Public companies generally do not report revenue for the ibuprofen/phenylephrine combination as a standalone product. Financial analysis therefore requires a category-based model rather than a product-level revenue series.

The likely trajectory is:

Period Financial direction Main driver
Near term Stable to modestly negative Existing inventory, continued legal sale, seasonal demand
Regulatory transition Negative for phenylephrine combinations Delisting, relabeling, retailer caution, consumer uncertainty
Post-reformulation Mixed Ibuprofen brand retention versus loss of congestion claim
Long term Lower product-specific revenue Substitution by pseudoephedrine, standalone analgesics, or new formulations

For a branded manufacturer, the key financial exposures are:

  • Lost units of phenylephrine-containing products;
  • Retailer delistings or reduced shelf allocation;
  • Packaging write-offs;
  • Reformulation and regulatory expenses;
  • Advertising costs for replacement products;
  • Cannibalization by the manufacturer’s own ibuprofen or pseudoephedrine products;
  • Potential loss of premium pricing versus private-label products.

Haleon identifies Advil and other consumer-health brands as material products within its portfolio, but public reporting does not isolate revenue for Advil Sinus Congestion & Pain or the ibuprofen/phenylephrine combination. Therefore, any precise product-level revenue estimate would be unsupported by public company disclosures. (Haleon, 2025)

What formulation patents and manufacturing barriers matter?

The active ingredients are relatively easy to source, and immediate-release tablets are straightforward to manufacture at scale. The main technical barriers are commercial execution and quality control.

Relevant manufacturing considerations include:

  • Uniform distribution of low-dose phenylephrine;
  • Tablet hardness and dissolution performance;
  • Stability under humidity and temperature variation;
  • Compatibility of ibuprofen with excipients;
  • Packaging controls for shelf life;
  • Consistent content uniformity;
  • Rapid relabeling if the decongestant indication changes.

Formulation know-how can support supply reliability and product quality, but it is unlikely to prevent generic substitution. A manufacturer with an integrated OTC supply chain can respond faster to FDA developments and retailer demands than a smaller supplier.

Are Paragraph IV challenges relevant?

Paragraph IV litigation is generally not the central pathway for ordinary monograph-compliant OTC products. Paragraph IV challenges apply to patents listed for approved drug applications, mainly under the Hatch-Waxman framework. Standard ibuprofen/phenylephrine products usually compete without a modern patent barrier requiring a paragraph IV filing.

Paragraph IV exposure could arise if a specific product is marketed under an NDA with listed patents covering a formulation, dosage form, or manufacturing process. That would require product-specific review of the FDA application and Orange Book listings. The broad combination category should not be treated as paragraph IV-protected.

Which companies are challenging the market leaders?

The competitive challenge is fragmented rather than concentrated in one branded rival.

Key participants include:

  • Haleon, through Advil-branded sinus and cold products;
  • Perrigo, through store-brand and private-label OTC products;
  • Kenvue, through Tylenol and related cold products;
  • Reckitt, through Mucinex and other respiratory products;
  • Retail pharmacy chains and mass merchants selling private-label equivalents;
  • Generic manufacturers supplying tablets, caplets, and liquid-filled formats.

The most consequential competitors may be retailers because they can replace a branded product with a private-label equivalent while preserving shelf space and category sales.

What litigation and settlement agreements affect the product?

No broad, category-defining patent litigation or settlement agreement is central to the ibuprofen/phenylephrine market. The primary legal issue is FDA administrative action concerning oral phenylephrine.

Potential litigation could arise from:

  • Challenges to FDA’s final monograph decision;
  • Consumer claims concerning efficacy representations;
  • False-advertising disputes;
  • Trademark or trade-dress copying;
  • Product-liability claims involving ibuprofen adverse events;
  • Contract disputes over private-label supply.

These risks are distinct from patent litigation. The FDA process is more likely to affect revenue than a generic patent settlement.

What generic launch scenarios exist?

Three launch scenarios are commercially plausible.

Scenario 1: Continued sale during FDA review

Manufacturers continue selling existing products, but retailers reduce forward inventory. Branded products retain seasonal demand, while generic prices remain under pressure.

Scenario 2: Phenylephrine claim removal

Manufacturers relabel or discontinue the combination. Ibuprofen-only products may retain pain and fever demand, but the product loses its congestion-related premium and consumer relevance.

Scenario 3: Shift to pseudoephedrine combinations

Manufacturers migrate toward ibuprofen/pseudoephedrine products. This may preserve the dual-symptom proposition but introduces purchase controls, behind-the-counter handling, and state compliance costs.

The most exposed products are those whose packaging, advertising, and consumer recognition depend heavily on "sinus congestion" relief.

What geographic coverage matters?

The FDA action is U.S.-specific. Other jurisdictions may maintain different positions on oral phenylephrine, impose different monograph requirements, or permit different combinations and claims.

Region Commercial implication
United States Highest immediate regulatory risk from FDA proposed removal
Canada Separate Health Canada review and labeling framework
European Union National and EU-level OTC requirements vary by product and indication
Latin America Market access and labeling rules vary widely
Asia-Pacific Local registration, monograph, and combination rules determine availability

A multinational manufacturer cannot assume that a U.S. reformulation automatically applies globally. However, global packaging simplification and supply-chain consolidation may encourage harmonized changes.

Key Takeaways

  • Ibuprofen remains commercially strong as an OTC analgesic.
  • Oral phenylephrine is the principal weakness in the combination.
  • FDA’s proposed removal of oral phenylephrine from the OTC monograph creates material relabeling and discontinuation risk.
  • The combination has limited practical patent protection and faces established generic competition.
  • Orange Book and Paragraph IV issues are usually secondary to monograph compliance, trademarks, formulation rights, and FDA rulemaking.
  • Public companies do not generally disclose standalone revenue for ibuprofen/phenylephrine products.
  • The most likely financial outcome is pressure on phenylephrine-containing products, followed by migration toward ibuprofen alone, pseudoephedrine combinations, or alternative congestion products.
  • Retailers and private-label suppliers have significant negotiating power because manufacturing complexity is relatively low.

FAQs

Is ibuprofen and phenylephrine hydrochloride being discontinued?

Not immediately. FDA proposed removing oral phenylephrine from the OTC monograph, but products may continue to be marketed during the regulatory process. Final timing depends on FDA’s final order and compliance requirements.

Does the FDA action affect ibuprofen?

No. The action concerns oral phenylephrine’s use as a nasal decongestant. Ibuprofen remains an accepted OTC analgesic, antipyretic, and anti-inflammatory ingredient.

Is Advil Sinus Congestion and Pain protected by patents?

The product category has limited practical patent protection. Any active formulation patent would be product-specific and would not prevent generic manufacturers from selling ordinary ibuprofen/phenylephrine products outside the protected claims.

Will pseudoephedrine replace phenylephrine in cold medicines?

Pseudoephedrine is a likely substitute for some products because it has stronger accepted decongestant positioning. Its use is constrained by federal purchase controls, retailer procedures, and state restrictions.

Is there a separate stock-market investment case for this combination?

Usually not. Manufacturers report broader consumer-health segments rather than standalone combination-product revenue. Investment analysis should focus on portfolio exposure, brand strength, OTC category growth, reformulation costs, retailer relationships, and the company’s ability to shift consumers to replacement products.

References

  1. Food and Drug Administration. (2023). Nonprescription drugs advisory committee meeting: Oral phenylephrine efficacy discussion. U.S. Department of Health and Human Services.

  2. Food and Drug Administration. (2024). Proposal to remove oral phenylephrine from the OTC monograph. U.S. Department of Health and Human Services.

  3. Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

  4. Haleon plc. (2025). Annual report 2024. Haleon plc.

  5. U.S. Food and Drug Administration. (2025b). Over-the-counter monograph drug products. U.S. Department of Health and Human Services.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.